Myeloid-derived Suppressor Cells As A Potential Therapeutic Target For Women With Early Miscarriage | 40686
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

2nd International Conference on Biotechnology and Healthcare

Auckland, New Zealand
Google scholar citation report
Citations : 1514

Journal of Biotechnology & Biomaterials received 1514 citations as per google scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Myeloid-derived suppressor cells as a potential therapeutic target for women with early miscarriage

6th World Congress on Biotechnology

Rohini Ravindran Nair1, Pratima Sinha2, Anuradha Khanna1 and Kiran Singh1

1Banaras Hindu University, India 2University of Maryland, USA

ScientificTracks Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.C1.043

The etiologies of first trimester loss are multifactorial and often remain unknown, certain risk factors increase the likelihood of pregnancy loss. To date there are many factors known to cause EPL but due to very heterogeneous condition of EPL or RPL, it still remains unresolved and unexplained. The identification of the underlying causes of pregnancy loss is important for developing more successful treatments for women experiencing RPL and thereby preventing subsequent pregnancy loss. A multitude of immunomodulatory properties of the fetal-maternal interface have evolved to allow the survival of the immunologically distinct fetus without an attack from the maternal immune system. To identify the contribution of inflammatory molecule we studied the level of S100A8 the inflammatory protein and MDSCs the cells regulating its expression in pregnancy loss patients. The contribution of S100A8 and myeloid-derived suppressor cells (MDSC) in patients suffering from early or recurrent miscarriage is unknown. S100A8 is a calcium binding proteins and is found at high levels in the extracellular milieu during inflammatory conditions. MDSC are implicated in modulation of T-cell response in healthy pregnancies: However, the role of MDSC in patients suffering from miscarriage has not been studied. S100A8 level was analyzed by real time PCR, Western Blotting and ELISA. MDSC level was assessed by flow Cytometry and Immunostaining in blood and endometrial decidua respectively. Activation of T-cells was determined by MTT proliferation and IL-2 ELISA assays. The miscarriage patients harbor increased level of S100A8 and reduced level of functionally suppressive MDSC in blood and endometrium as compared to healthy control women with successful pregnancies. These results suggest S100A8 and MDSC are inversely corelated. MDSC level regulates maternal tolerance in healthy pregnancies and that drug inducing MDSC could have therapeutic implication in the miscarriage patients.

Rohini Ravindran Nair has completed his PhD from Banaras Hindu University. She has received Marie-Curie CO-INVEST Fellowship. She is at present working as a Postdoctoral Fellow in San Raffaele Scientific Institute, Italy. She has published 14 papers in reputed journals and a book chapter.

Email: [email protected]